Allergan Stock Buy Or Sell <HD>

: Analysts are currently focused on AbbVie's ability to offset the loss of exclusivity for its flagship drug, Humira, through newer immunology drugs like Skyrizi and Rinvoq .

As of April 2026, . The company was acquired by AbbVie (NYSE: ABBV) in a $63 billion deal that officially closed on May 8, 2020. allergan stock buy or sell

If you previously held Allergan (AGN) shares, they were converted during the 2020 merger according to the following terms: AbbVie Completes Transformative Acquisition of Allergan : Analysts are currently focused on AbbVie's ability

: For the full year 2026, management has guided for net revenues of approximately $67 billion, representing 9.5% growth. Historical Acquisition Terms If you previously held Allergan (AGN) shares, they

: The Allergan division, now branded as Allergan Aesthetics , continues to lead the global medical aesthetics market with products like Botox.

Since the acquisition, AbbVie has used Allergan’s aesthetics and neuroscience portfolios to diversify its revenue.